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Abstract 
Glomerular filtration rate (GFR) is usually determined by estimation of iothalamate (IOT) clearance. We have devel-
oped and validated an accurate and robust method for the analysis of IOT in human plasma and urine. The mobile 
phase consisted of methanol and 50 mM sodium phosphate (10:90; v/v). Flow rate was 1.2 mL/min on a C18 reverse 
phase column, Synergi-hydro (250 × 4.6 mm) 4 µm 80 Å, with an ultraviolet detector set to 254 nm. Acetonitrile 
was used for the deproteination and extraction of IOT from human plasma and urine. Precision and accuracy were 
within 15% for IOT in both plasma and urine. The recoveries of IOT in urine and plasma ranged between 93.14% and 
114.74 and 96.04–118.38%, respectively. The linear range for urine and plasma assays were 25–1500 and 1–150 µg/
mL respectively. The lower limits of detection were 0.5 µg/mL for both urine and plasma, with no interference from 
plasma and urine matices. This method has been fully validated according to FDA guidelines and the new HPLC assay 
has been applied to a new formulation of IOT (Conray™ 43), to calculate GFR in healthy volunteers. The new method 
is simple, less expensive and it would be instrumental in future clinical and pharmacokinetic studies of iothalamate in 
kidney patients.
Keywords: Iothalamate, Iothalamic acid, GFR, Glomerular filtration rate, Human urine and plasma, HPLC
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Renal function is best studied with accurate measure-
ment of glomerular filtration rate (GFR) in pre-clinical 
studies, clinical practice and clinical trials [1–3]. Inulin 
[4, 5] and creatinine [6, 7] clearances are accepted refer-
ence standards for determining GFR but are expensive 
and laborious. Colorimetric assays are used to detect 
Inulin, which is very expensive and also in very short sup-
ply and many problems with the assay [8]. 24-h creatinine 
clearance overestimates GFR in patients with poor renal 
function and a variety of other glomerular diseases and 
drugs can make creatinine clearance and serum creati-
nine a poor markers of GFR estimation [9, 10]. GFR esti-
mated from serum creatinine using prediction equations 
may result in unpredictable error when the diagnosis 
of chronic kidney disease is unknown [1–3, 6, 7, 11–
23]. Cystatin C, a low molecular weight protein that is 
produced by nucleated cells at a constant rate and is then 
filtered by glomeruli and reabsorbed and catabolized by 
tubular epithelial cells, has been suggested as an alter-
native for creatinine [24–26]. It seems to be affected by 
factors other than renal function alone [27–33]. Usually, 
iothalamate (IOT) clearance [2, 3, 15, 20, 22, 34, 35] are 
used to measure GFR. Mostly, radioactive compounds 
are also used to perform IOT clearances [36–38], which 
have radioactive health and safety issues. That’s why we 
have used non-radioactive IOT for analysis.
Recently, several high-performance liquid chromatog-
raphy (HPLC) techniques have been published for the 
analysis of IOT in serum and urine, but are not without 
problems [8, 39–46]. Initial methods for sample prepara-
tion consisted of several time-consuming extraction and 
evaporation steps. Also, the sensitivity of some of the 
previously reported assays is not great, for example, an 
HPLC–UV method published by Farthing et al. had a lin-
ear range for the detection of IOT in plasma from 10 to 
50 µg/mL [40]. Later developed procedures reduced sam-
ple preparation to a single precipitation step or an ultra-
filtration step prior to analysis. LC–MS methods are also 
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used [36, 47] along with capillary electrophoresis [34], 
both of which are more expensive and require specialized 
training and expertise to operate.
Herein we report on a method using standard C18 col-
umns, which allow estimation of IOT in a single chro-
matographic run along with a simple and inexpensive 
sample preparation method using acetonitrile precipita-
tion as compared to ultrafiltration as done in the past. 
We don’t require a very expensive instruments to carry 
out such analysis. Our extraction procedure does not 
require extensive sample extraction procedures, shows 
no peak deterioration with high injection volume. The 
sample preparation method is a much improved version 
of existing methods [8, 41, 43, 48], notably because the 
present work describes a more sensitive and simple assay 
for IOT in a relatively large number of patients, who are 
given a new formulation of IOT (Conray 43™). Further-
more, IOT concentrations were determined in both, 
plasma as well as urine samples to calculate GFR, and 
lastly, we report a fully validated assay according to FDA 
guidelines.
Our aim was to develop an inexpensive, robust and reli-
able HPLC method for analysis of IOT in human plasma 
and urine along with comparing two sample preparation 
methods (ACN precipitation method compared to ultra-
filtration) using two internal standards allopurinol and 
BHET.
Experimental
Materials
Iothalamic acid (P/N USP34500-2) was bought from 
Promochem, Welwyn Garden City, Herts, UK. Internal 
Standards Allopurinol (P/N H-9006), Hydroxyethyl-The-
ophylline (BHET) (P/N H-9006) were purchased from 
Sigma, Chemical Co, Poole, Dorset, UK, as was Sodium 
phosphate (Monobasic-ACS reagent grade). HPLC grade 
acetonitrile, methanol and water were purchased from 
Hichrom Ltd, Berkshire, UK. Drug free control serum 
was purchased from Charter House Clinical Research 
Unit, Slough, UK.
Micro-centrifuge tubes 1.5  mL, Kimble Amber auto-
sampler vials, glass inserts, caps and 12  ×  75  mm test 
tubes were all bought from Fisher Scientific Loughbor-
ough, UK. Other instruments used were heater block 
with nitrogen cannula to evaporate samples, platform 
mixer or vortex to mix samples.
Apparatus and chromatographic conditions
Hewlett Packard model 1100 high performance liquid 
chromatography (HPLC) system consisted of HP 1100 
series degasser, quaternary pump, auto-injector, column 
heater and a UV detector. The system was controlled 
through Chemstation software, version B.04.02 loaded 
on a HP (Vectra Vm) series computer with a printer. 
Mobile phase consisted of Methanol: 50  mM Sodium 
Phosphate (10:90) (unadjusted about PH 4.67). Flow rate 
was 1.2  mL/min, column used was Synergi-4µ-hydro-
RP-80A (250 × 4.6 mm) with a guard column Symmetry 
Shield RP-18 (15 mm × 4.5 mm, 5 µm) with an ultravio-
let Detector set at 254 nm, column temperature was set 
to 30  °C, injection volume was 10 µL, run time for the 
run was 15  min. All analyses were performed at room 
temperature.
Solution preparation
Stock solutions
Preparation of stock iothalamic acid solutions 10 mg/mL. 
Solutions were prepared in duplicate one for calibration 
standards and one for quality control. 100 mg of iothalamic 
acid was weighed out and placed in a 10  mL volumetric 
flask. Then dissolved in 10 mL methanol and stored in the 
refrigerator (0–5 °C) (Final conc. = 10 mg/mL). 10 mg of 
Allopurinol was weighed out and placed in a 10 mL vol-
umetric flask. It was dissolved in 10 mL of methanol and 
stored in the refrigerator (0–5 °C) (Final conc. = 1.0 mg/
mL). β-Hydroxyethyl-Theophylline (BHET), stock inter-
nal standard (IS) solution was prepared having a concen-
tration of 1.0  mg/mL. 10  mg of BHET was weighed out 
and placed in a 10  mL volumetric flask. It was dissolved 
in a 10 mL of methanol. The solutions were stored in the 
refrigerator at 0–5 °C (Final conc. = 1.0 mg/mL) and these 
solution was marked as IS-Stock.
Working solutions, calibrants and quality controls
Working internal standard solution was prepared by dilut-
ing 1.0 mL of IS Stock solution in a 10 mL volumetric flask 
and diluted to 10 mL with acetonitrile (final conc. 0.1 mg/
mL Allopurinol). Working iothalamic standard solutions 
were prepared by dissolving 1  mL of stock iothalamic 
(IOT) solution (conc. = 10 mg/mL) in a 10 mL volumetric 
and diluted with 9 mL of methanol. Iothalamic acid stock 
solutions were stored in 15 mL polypropylene screw cap 
test-tube and stored at 0–5  °C (refrigerated). Calibrants 
were prepared by serial dilutions and then the volumes 
were pipetted into clean, labelled 1.5 mL micro-centrifuge 
tubes, and evaporated to dryness and reconstituted with 
100  µL of control plasma or urine to obtain the desired 
concentrations. Quality control solutions were prepared 
in the concentration of 1, 2, 20 and 120 µg/mL for plasma 
and 25, 40, 200 and 1200 for urine. Calibration curve were 
made in plasma in the range 1–150 µg/mL and in urine in 
the range 25–1500 µg/mL.
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Phosphate buffer
50  mM monobasic sodium phosphate was prepared by 
weighing out 6 g of sodium phosphate (Monobasic) and 
dissolving in 1000 mL of HPLC water, and stored at room 
temperature.
Sample preparation and extraction
For plasma samples, working standards and controls 
were evaporated under a stream of nitrogen and 100 µL 
of control plasma was added for calibrants and quality 
control samples preparation, the samples were mixed vig-
orously for 5–10 s using a platform (vortex) mixer. 50 μL 
of working internal standard solution of allopurinol was 
added to each sample, standard and quality control. Next 
300 μL of acetonitrile was added to each sample, standard 
and quality control. All samples were mixed vigorously 
and centrifuged at 1200×g for 10 min at room tempera-
ture (18–25  °C). The supernatant were transferred into 
clean, labelled 12 × 75 mm tubes and evaporated to dry-
ness under a gentle stream of nitrogen. The dried resi-
due was reconstituted with 100 µL of mobile phase and 
transferred to a glass insert inside a 2 mL standard HPLC 
auto injector vial. These were vortex mixed and centri-
fuged for 5 min at 1200×g and 10 µL of the supernatant 
injected onto the HPLC system.
For urine samples, working standards and quality con-
trols were evaporated under a stream of nitrogen and 
reconstituted in 100 μL of tenfold diluted blank urine. 
These were mixed vigorously for 5–10 s using a platform 
(vortex) mixer. This urine solution was then placed in a 
1.5  mL micro-centrifuge tube and 50 μL mobile phase 
containing the internal standard (100 μg/mL Allopurinol) 
was added to each sample, standard and quality controls. 
These are mixed vigorously and transferred to a glass 
insert inside a Kimble vial and 10 μL was injected onto 
the HPLC system.
Calculations
Peak areas/heights for each peak were obtained from the 
computer data capture system. The standard curves were 
generated by weighted (1/y2) linear regression of peak 
area/height ratios of IOT to allopurinol versus supple-
mented urine concentrations. Quantitation of unknown 
samples were estimated by applying the linear regression 
equation of the standard curve to the unknown sample’s 
peak area/height ratio.
Validation
All frozen samples (control and test serum samples) were 
thawed for approximately half an hour at room tem-
perature, vortexed before processing and transferred 
to appropriately labelled tubes. The usual analytical run 
consisted of two control blank matrix samples, calibra-
tors S1-S8, quality control samples (minimum two sets 
of quality control low -QCL, quality control medium—
QCM and quality control high–QCH per run), one set 
run after blanks and calibrators and then after approxi-
mately every 15 test samples. Mobile phase was injected 
between the analytical control samples and the blanks 
and also after the calibrators to minimise carryover. Each 
analytical run was prepared and assayed within a 28-h 
period.
A quality control was rejected on the standard curve 
estimations if deviated 15% or more, or in case of limit 
of quantitation (LOQ), quality controls deviating 20% 
or more was rejected. Any sample was discarded if a 
peak of interest had obvious chromatographic inter-
ference. A sample, standard, or quality control sample 
was rejected if the internal standard (peak height/area/
injected volume) was one standard deviation from the 
normal.
Precision/accuracy and LOQ
The accuracy and precision of the method was deter-
mined by assaying 1 mL aliquots of blank human plasma 
and urine was fortified with four quality control (QC) 
samples of concentrations 1, 2, 20 and 120  µg/mL for 
plasma and 25, 40, 200 and 1200  µg/mL for urine. To 
assess the inter-assay precision and accuracy, samples 
were analysed on five separate days. To assess the intra-
assay precision, these same QC concentrations were ana-
lysed during 1 day. Precision and accuracy are reported 
as percent coefficient of variation and percent accuracy 
[(observed −  expected) ×  100/expected concentration], 
respectively.
The results of QC sample analysis provide the basis for 
accepting or rejection the run. Variability of the quality 
control samples was assessed from the validation proce-
dure. For each individual QC, the acceptance criterion 
was not more than a 15% deviation from the nominal 
value for accuracy. LOQ was defined as the lowest con-
centration of an analyte in a sample that was determined 
with acceptable precision and accuracy under the stated 
operational conditions of the method. An acceptable 
range for LOQ was nominal value ±20%.
Specificity
The responses of interfering peaks at the retention time 
of the analyte were less than 20% of the response of an 
LOQ standard. Responses of interfering peaks at the 
retention time of the internal standard were ≤5% of the 
response of the concentration of the internal standard to 
be used in studies which demonstrated the specificity of 
the validated analytical procedure.
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Linearity
The ratio of UV area response for the peak correspond-
ing to iothalamic acid in the HPLC chromatogram to the 
UV area response of the internal standard against the 
nominal concentrations of iothalamic acid represents 
the linearity. Applying linear regression to the calibra-
tion data obtained from seven calibration standards gives 
the equation of the linear line. A calibration point was 
rejected as an outlier if the back-calculated concentration 
for a calibrator (on the basis of the corresponding calibra-
tion curve) deviated more than 15% at all concentrations 
covered by the calibration range except at LOQ where 
the deviation of 20% was acceptable. A calibration curve 
was accepted with a minimum of 6 out 8 acceptable cali-
bration levels.
Recovery
The recovery of IOT from urine and plasma was deter-
mined by calculating the ratio of slopes of IOT standard 
curves against the slope of the same standards prepared 
in distilled deionized water.
Stability
Human plasma at concentration of QCL-2, QCM-20 
and QCH-120  µg/mL and urine samples at concentra-
tions QCL-40, QCM-200 and QCH-1200 were subjected 
to 3 freeze and thaw cycles. The results obtained after 
each freeze and thaw cycle was expressed as a percent-
age change from the results for QCL-40, QCM-200 and 
QCH-1200 in the intra-assay run (validation run-1, these 
samples were prepared fresh and had not experienced any 
freezing conditions). The test compound was considered 
to be stable if the percentage change from freshly prepared 
samples was within ±15% of the nominally spiked level.
GFR calculations
An effective way of assessing how well the kidneys are 
working is to calculate the glomerular filtration rate 
(GFR). GFR is a measurement of how many millilitres 
(mL) of waste fluid the kidneys can filter from the blood 
in a minute (measured in mL/min). A healthy pair of kid-
neys should be able to filter more than 90 mL/min. The 
result is called the estimated GFR or eGFR.
The IOT clearance was calculated by the formula
Here glomerular filtration rate was calculated by mul-
tiplying urine flow rate with concentration of IOT in 
urine divided by IOT concentration in plasma. The GFR 
was recorded in units of volume per time i.e.; mL/min. 
The following table shows the different stages of renal 
GFR =
Urine Concentration× Urine Flow
Plasma Concentration
function [49]. The urine flow was measured using uro-
flowmetry device, Flow-Med™ 1100 and measuring flow 
of urine over time.
Subjects
Twenty healthy young volunteers were recruited for the 
study. Each volunteer received a 1.5  mL bolus injection 
of Conray™ 43 containing 645 mg of iothalamate meglu-
mine (Malinkrodt Plc, Ireland) and a 5-mL sterile normal 
saline flush. To estimate GFR over 150 min period blood 
and urine samples were collected. Blood and urine sam-
ples were first collected after 60  min and then samples 
were collected every 30  min for three consecutive time 
interval. All samples were stored at −20 °C until analysed 
(within 1 month). Kingston University research ethics 
committee approved the study protocol and the volun-
teers provided informed written consent to participate 
in the study. This study was conducted according to the 
principles of the Declaration of Helsinki [50].
Results and discussion
Chromatography
A representative chromatogram of IOT and internal 
standard, are shown in Fig. 1. A representative chromato-
gram, showing an overlay of blank human serum and urine 
along with a representative chromatogram of urine and 
plasma, after injecting IOT in a human subject, is shown 
in Fig.  1. The chromatographic conditions were adapted 
from a previously published report [26]. The mobile phase 
elution of 10% methanol and 90% 50  mM sodium phos-
phate in water gave maximum separation. Both IOT and 
the internal standard showed sharp, well-defined peaks at 
retention times of 6.9 and 10.4 min, respectively.
Intra‑day and inter‑day precision and accuracy
The accuracy and precision of the method was deter-
mined by assaying 100 μL aliquots of human plasma 
fortified with 1, 2, 20 and 120 μg/mL of iothalamic acid 
(representing quality controls: LOQ, QCL, QCM and 
QCH respectively) and 25, 40, 200 and 1200 concen-
trations for human urine. These fortified samples were 
assayed by HPLC–UV. Intra-assay accuracy and preci-
sion for iothalamic acid in urine were calculated from 
results obtained from 6 replicate analyses of quality con-
trols each at 4 concentrations (1, 2, 20 and 120 μg/mL of 
iothalamic acid in human plasma, and 25, 40, 200 and 
1200 concentrations for human urine). Different stanges 
of renal function are given in Table  1 below.  The intra 
and    inter assay results show 1 μg/mL to be the limit of 
quantitation level for iothalamic acid in human plasma 
and 25  μg/mL for urine, using developed analytical 
method. These are summarised below in Table 2. 
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Specificity
Chromatogram showing plasma and urine samples from 
six subjects without any interference from endogenous 
compounds in the retention time regions of the internal 
standard and iothalamic acid.
Linearity
The plots were linear over the concentration range 
1–150 μg/mL IOT in human plasma and the fit statisti-
cally tested by slope, intercept and correlation coefficient 
(r2) and linear regression with 1/y*y fit was found to be 
suitable. For urine the plots were linear over the concen-
tration range 25–1500  μg/mL. None of the intercepts 
were significantly different from zero.
Recovery of calibration standards
Determination of recovery of iothalamic acid from 
human plasma and urine was determined by tak-
ing the UV area ratio response of iothalamic acid to 
internal standard in the extracted sample divided by 
the area ratio response determined in an un-extracted 
Fig. 1 A typical chromatogram is shown for iothalamic acid and internal standard (Allopurinol) in human plasma and urine with blanks overlay to 
show specificity
Table 1 Different stages of renal function
Stages GFR (mL/min) Kidney function
Stage 1 ≥90 Normal
Stage 2 60–89 Slight decrease
Stage 3 30–44 Mild decrease
Stage 4 15–29 Severe decrease
Stage 5 ≤15 Renal failure
Table 2 Summary of assay validation results
These values were well within the assay criteria for accuracy of nominal concentration ±15%
Analyte (µg/mL) QC Linear range LOD R2 Intra‑day (N = 6) Inter‑day (N = 12) Recovery
Precision, % CV Accuracy % Precision, % CV Accuracy %
Iothalamic acid in plasma 1 1–150 0.5 0.9985 4.56 86.33 13.16 90.08
2 9.46 112.5 12.87 102.58
20 14.96 100.74 11.52 96.6 96.05
120 2.66 99.88 2.65 98.99 118.38
Iothalamic acid in urine 25 25–1500 5 0.9992 4.31 97.54 4.45 95.91
40 3.96 88.49 3.86 90.91
200 2.23 114.96 6.68 108.33 93.14
1200 1.81 109.8 8.56 101.66 111.74
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sample and multiplied by 100 gave the percent 
recovery.
Stability of iothalamic acid in plasma to repeated freezing 
and thawing cycles
The QCL-2  µg/mL samples gave a mean result of 1.97, 
1.87 and 2.37 μg/mL (n = 6) with the corresponding per-
centage change from freshly prepared samples of 12.44, 
12.59 and −5.19% for freezing and thawing cycles 1,2 
and 3 respectively. The QCM-20 samples gave a mean 
result of 21.37, 20.73 and 20.20 μg/mL (n = 6) with the 
corresponding percentage change from freshly pre-
pared samples of −6.08, −2.87 and −0.26% for freezing 
and thawing cycles 1, 2 and 3 respectively. The QCH-
120 samples gave a mean result of 122.12, 121.99 and 
121.71 μg/mL (n = 6) with the corresponding percentage 
change from freshly prepared samples from time t = 0 to 
−1.89, −1.49 and −1.54% for freezing and thawing cycles 
1, 2 and 3 respectively. The data indicates that iothalamic 
acid was stable in plasma to at least 3 freezing and thaw-
ing cycles.
Stability of iothalamic acid in urine to repeated freeze/
thaw cycles
The QCL-40 samples gave a mean result of 37.63, 40.19 
and 36.07  μg/mL with the corresponding percentage 
change from freshly prepared samples of +6.31, −13.54 
and +1.88% for freeze and thaw cycles 1, 2 and 3 respec-
tively. The QCM-200 samples gave a mean result of 
208.34, 211.68 and 213.08  μg/mL with the correspond-
ing percentage change from freshly prepared samples of 
−9.38, +7.93 and −7.90% for freeze and thaw cycles 1, 2 
and 3 respectively. The QCH-1200 samples gave a mean 
result of 1144.84, 1192.05 and 1227.22  μg/mL with the 
corresponding percentage change from freshly prepared 
samples of −13.11, +9.53 and −7.37% for freeze and 
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Fig. 2 Plasma concentrations of iothalamate in 20 subjects after a single intravenous bolus injection of 1.5-mL Conray™ 43. Plasma iothalamate 
concentrations ranged between 4.32 and 16.36 μg/mL in the 20 subjects, error bars represents standard error of mean (SEM)
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thaw cycles 1, 2 and 3 respectively. The data indicates 
that iothalamic acid was stable in urine to at least 3 freeze 
and thaw cycles.
Applications in humans
Plasma IOT concentration was plotted against time after a 
single injection (1.5-mL Conray™ 43) as shown in Fig. 2. 0 
point on the graph shows the time before the bolus injec-
tion was administered. Since the first sample collection 
and measurement was carried out at 60  min, it is quite 
likely that the peak concentration might have spiked at a 
much earlier time point than 60 min. However, the main 
aim of this part of the study was to measure GFR rates. Fig-
ure 2 shows that on the average the IOT reaches its peak 
plasma concentration in an hours’ time and then it starts 
to decline. The concentration of IOT in plasma ranged 
between 4.32 and 16.36 µg/mL in 20 healthy volunteers.
Figure  3 shows how the urine IOT concentration 
changed over time after a single injection (1.5-mL 
Conray™ 43). The figure also shows how the average con-
centration of IOT clearance reaches its maximum in an 
hour time and then it starts to decline. The concentration 
of IOT in urine ranged between 76.92 and 311.32 µg/mL 
in 20 healthy volunteers.
Figure 4 shows the GFR value of 20 volunteers in mL/
min against time. GFR was calculated by dividing (con-
centration of urine excreted × flow of urine) by concen-
tration of plasma for each subject. The 5 columns under 
each subject represent the five time points of sample col-
lection (0, 60, 90, 120 and 150). Subjects 1, 2, 3, 4, 5, 6, 7, 
9, 15, 16, 18, 19 and 20 shows that the glomerular filtra-
tion rate was optimum at around 90 min, and subjects 10, 
11, 12, 13 and 14 show a high renal clearance at 60 min, 
while 17 shows maximum GFR from 90 to 120  min. 
Moreover, subject 8 shows maximum GFR before IOT 
injection at 0 min.
Figure 5 shows a comparative concentration–time pro-
file of 20 volunteers, where blood and urine was collected 
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Fig. 3 Urine concentrations of iothalamate in 20 subjects after a single intravenous bolus injection of 1.5-mL Conray™ 43. Urine iothalamate con-
centrations ranged between 76.92 and 311.32 μg/mL in the 20 subjects, here error bars represent SEM
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at 60, 90, 120 and 150  min from subjects after a single 
intravenous bolus injection of 1.5-mL Conray™ 43. The 
figure describe how the GFR varies between subjects at 
different time intervals.
In conclusion, we report on a new, simple and sensi-
tive method for the measurement of IOT, which was then 
validated and used to estimate GFR. The current method 
employed a new internal standard, allopurinol (after try-
ing BHET as well) and had the added advantage of only 
a single step extraction from plasma and urine. The 
method was further validated in healthy volunteers and 
showed that GFR was rapidly estimated with minimal 
blood and urine sampling. GFR determination by IOT 
clearance is safe in diabetic patients with mild to mod-
erate renal impairment [51]. Furthermore, single plasma 
sampling 4 h after injection of IOT was safely and accu-
rately undertaken to determine GFR. This enables the 
technique to be used more frequently in clinical practice 
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Fig. 4 GFR- time profile of 20 volunteers, where blood and urine was collected at 60, 90, 20 and 150 min from subjects after a single intravenous 
bolus injection of 1.5-mL Conray™ 43, here error bars represents SEM
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as it reduces the cost of GFR determination, and allows 
the procedure to be undertaken easily in an outpatient 
setting.
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